Several new anti-inflammatory and anti-cytokine agents, including but not limited to direct upstream inhibitors of the NLRP3 inflammasome, and natural inhibitors of IL-6, can be expected to be used in atherosclerosis by targeting the NLRP3, IL-1, IL-6 to CRP pathway. Here, NLRP3 is linked to atherosclerosis.